Ongoing monitoring is essential for safe, effective treatment. From regular lab work and bone age X-rays to dose adjustments and growth velocity tracking, here's what parents need to know about how your child's progress is measured and managed throughout therapy.
Growth hormone therapy is not a "set it and forget it" treatment. Careful, ongoing monitoring is a critical part of ensuring your child gets the best possible outcome safely. Here's why it matters:
Regular monitoring confirms that treatment is working as expected and your child is responding well to therapy.
As your child grows, their dose needs to be recalculated and optimized. Monitoring provides the data to make precise adjustments.
Routine lab work and check-ups catch any potential side effects early, when they are easiest to manage or resolve.
Bone age X-rays reveal how much growth potential remains, helping maximize the treatment window before growth plates close.
Every monitoring visit generates objective data — growth velocity, IGF-1 levels, bone maturation, metabolic health — that your child's physician uses to make informed, evidence-based decisions about treatment. This is not guesswork; it is precision medicine applied to your child's growth.
During active growth hormone therapy, your child will be seen by a physician on a regular schedule. Here's what a typical monitoring visit includes:
Blood work is a cornerstone of growth hormone therapy monitoring. Each test serves a specific clinical purpose:
Ensures growth hormone is converting properly in the body. IGF-1 is the primary marker used to guide dosing decisions — it should fall within an age-appropriate target range.
Growth hormone can affect thyroid function, and low thyroid levels can impair growth. Thyroid panels are monitored regularly to ensure normal function throughout treatment.
Growth hormone affects insulin sensitivity. Monitoring glucose metabolism ensures your child maintains normal blood sugar levels and metabolic health during therapy.
Assesses liver and kidney function to confirm the body is processing the medication safely. This is standard monitoring for any ongoing hormone therapy.
A general health screening that checks red and white blood cell counts, hemoglobin, and platelets. Helps identify any unexpected changes during treatment.
Bone age assessment is one of the most important monitoring tools in growth hormone therapy. It tells the physician how much growth potential your child has remaining.
Growth hormone dosing is not static. As your child grows and their body changes, the dose must be recalibrated to maintain optimal effectiveness:
It's a common misconception that more growth hormone means more growth. In reality, exceeding the optimal dose can increase the risk of side effects without meaningfully improving growth velocity. Your child's physician uses lab data and clinical response to find the right balance — optimization is the goal, not maximization.
Growth hormone therapy is not lifelong for most children. The decision to stop treatment is based on objective clinical data and is made collaboratively between the physician and your family:
Regular monitoring helps maximize every inch of growth potential before growth plates close permanently. Once closed, no medication can increase height. This is why consistent monitoring and timely dose adjustments matter — every visit is an opportunity to optimize your child's remaining growth window.
Monitoring is part of the overall treatment investment. Our clinics are private, cash-pay practices — no insurance is accepted. Full cost transparency is provided upfront:
Blood work is typically performed every 3 to 6 months during active growth hormone therapy. The most important markers include IGF-1 levels (to guide dosing), thyroid function, glucose metabolism, and general health panels. Your physician may order labs more frequently during the initial months of treatment or after a dose adjustment to ensure optimal response.
A bone age X-ray is a simple, painless X-ray of the left hand and wrist. The image is compared to standard reference images to determine skeletal maturity — how "old" your child's bones are compared to their actual age. This tells the physician how much growth potential remains. A bone age that is younger than the child's chronological age often means there is more time and opportunity for growth. Bone age X-rays are typically performed annually during treatment.
Dose adjustments are based on several factors: the child's current weight (since dosing is weight-based), IGF-1 blood levels (which should fall within a target range), and the child's growth velocity response. If IGF-1 levels are too low or growth velocity is below expectations, the dose may be increased. If IGF-1 levels are above the target range, the dose may be reduced. The goal is optimization — higher doses are not always better and may increase the risk of side effects.
Treatment typically ends when growth plates are approaching closure, which occurs around bone age 14–16 in girls and 16–18 in boys. Other indicators include reaching the target height goal, or when growth velocity slows to less than 1 inch per year despite ongoing therapy. The decision to stop treatment is always made by the treating physician based on clinical data, including bone age X-rays and growth velocity measurements.
Our care team reviews your child's growth history and helps you understand whether a specialist evaluation may be right for your family. No cost. No obligation. Available nationwide via telemedicine.
Medical Disclaimer: HGHKids.com is a privately operated educational and referral platform. We do not diagnose, treat, or prescribe. All medical decisions are made by licensed physicians following appropriate evaluation. Information on this site is for educational purposes only and does not constitute medical advice.